Article

Covalent Binding of Boronic Acid-Based Inhibitor GSK4394835A to Phosphodiesterase 3B, a Drug Target for Cardiovascular Disease

2025-10-22

Abstract excerpt

Boronic acids have become increasingly prominent in the pharmacopoeia ever since the US Food and Drug Administration approved Bortezomib (Velcade) for the treatment of multiple myeloma more than 20 years ago. Since then, four additional boronic acid-based drugs have been approved for clinical use in the treatment of cancer, fungal and bacterial infections, and eczema. The boron atom is inherently electrophilic due...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 65b56ed1-9f35-5ef7-9deb-f0ff5615d30b
DOI: 10.1101/2025.10.22.684020

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest

Covalent Binding of Boronic Acid-Based Inhibitor GSK4394835A to Phosphodiesterase 3B, a Drug Target for Cardiovascular DiseaseDOI 10.1101/2025.10.22.684020Read

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine KinaseSemantic proximity Read

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's diseaseSemantic proximity Read

Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.Semantic proximity Read

Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides.Semantic proximity Read

A GIBAC-based selectivity strategy for the design of PDE5 inhibitors to minimize visual disturbancesSemantic proximity Read

The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of ( S )-2-((2-(1-Isopropyl-1 H -1,2,4-triazol-5-yl)-5,6-dihydrobenzo[ f ]imidazo[1,2- d ][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)Semantic proximity Read

Structural basis for the catalytic mechanism of human phosphodiesterase 9.Semantic proximity Read

Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine.Semantic proximity Read

Targeting GSK-beta with Peptide Inhibitors: A Rational Computational Strategy for Alzheimer's Disease InterventionSemantic proximity Read

Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode.Semantic proximity Read